IL17A and psoriasis vulgaris: Thus, our data imply that inhibition of IL-36 signaling constitutes an attractive, alternative approach for the treatment of IL-17A-driven plaque psoriasis, which may also effectively inhibit psoriasis-associated comorbidities.